That is the big question unfortunately. From what we are being...

That is the big question unfortunately. From what we are being told in presentations it would appear we are achieving results that are way ahead of the field.

We can get omomyc into cells where its original manufacturer can't.

We can take various cell types and select a fpp that will not only enter but escape endosome.

We have a myc inhibit or that is more effective than omomyc and the ability to deliver it within cells

We have cell penetrating peptides that are many times more effective than current best TAT.

We recently received our largest milestone payment from a partner as a deal extension for research into novel biologics. They could have walked away but instead paid one of our largest milestone payments to date to continue tghe research.

I like many believe we have made excellent progress. The only question seems to be if things are try as good as it appears tthey why are we not getting more large deals thrown at us? It appears we are achieving things no one else is yet currently we still only have one large pharma deal. If we could get validation from another pharma that at least another branch of our research is actually of interest or financial worth then we could take off. Heres hoping. Currently it seems we have had the so called holy grail if cell penetration and endosomal escape gor a considerabl e time now yet so far nothing offered by potential partners, and no way we can fund huge trials alone.